Darolutamide (ODM-201) for the treatment of prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. GLOBOCAN 2012: prostate cancer, estimated incidence, mortality and prevalence worldwide in 2012. 2015. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp
   Google Scholar
• American Cancer Society. Cancer facts and figures 2016. Atlanta (GA): American Cancer Society; 2016. p. 500816.
   Google Scholar
• Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v69–v77.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN: National Comprehensive Cancer Network clinical practice guidelines in oncology: prostate cancer. Version 1. 2017. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
   Google Scholar
• Cookson MS, Lowrance WT, Murad MH, et al. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015;193:491–499.
   PubMed Web of Science ®Google Scholar
• Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9:90–96.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–160.
   PubMed Web of Science ®Google Scholar
• Wadosky KM, Koochekpour S. Therapeutic rationales, progresses, failures, and future directions for advanced prostate cancer. Int J Biol Sci. 2016;12:409–426.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Albiges L, Loriot Y, et al. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15:1007–1017.
   PubMed Web of Science ®Google Scholar
• Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela T, et al. ARAMIS trial: efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer. J Clin Oncol. 2016;34(suppl 15): Abstr TPS5094. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS5094
   Google Scholar
• Moilanen A, Riikonen R, Oksala R, et al. ODM-201 – new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. Presented at: European Cancer Congress; 2013 Sep 27–Oct 1; Amsterdam, The Netherlands. Abstract E17-2119.
   Google Scholar
• Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975–985.
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Prien O, Vuorela A, et al. Pharmacokinetics, mass balance, and metabolite profiling of ODM-201 in healthy men: an open-label, phase 1 trial. Presented at: American Association of Pharmaceutical Scientists; 2016 Nov 13–17; Denver, CO.
   Google Scholar
• Massard C, Penttinen HM, Vjaters E, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69:834–840.
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Reza M, Jones R, Aspegren J, et al. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. Eur Urol Focus. 2016;2:547–552.
   Google Scholar
• Fizazi K, Massard C, Bono P, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in castration-resistant, CYP17 inhibitor-naïve prostate cancer: results from extended follow-up of the ARADES trial. Eur Urol Focus. Forthcoming, 2017. Available from: https://doi.org/10.1016/j.euf.2017.01.010
   Google Scholar
• Shore ND, Tammela TL, Massard C, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-naïve and CYP17 inhibitor-naïve patients: follow-up from the ARADES and ARAFOR trials. Eur Urol Focus. Forthcoming, 2017. Available from: https://doi.org/10.1016/j.euf.2017.01.015
   Google Scholar
• Shore N, Bono P, Massard C, et al. ODM-201 and the CNS: a clinical perspective. J Clin Oncol. 2014;32(suppl 4): Abstr 275. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.4_suppl.275
   PubMed Web of Science ®Google Scholar
• Zytiga (abiraterone acetate) [prescribing information]. Horsham (PA): Janssen Biotech, Inc; 2016.
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Xtandi (enzalutamide) [prescribing information].. Northbrook (IL): Astellas Pharma US, Inc.; 2016.
   Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Santer FR, Erb HH, McNeill RV. Therapy escape mechanisms in the malignant prostate. Semin Cancer Biol. 2015;35:133–144.
   PubMed Web of Science ®Google Scholar
• Crona DJ, Milowsky MI, Whang YE. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther. 2015;98:582–589.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038.
   PubMed Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70:963–970.
   PubMed Web of Science ®Google Scholar
• Li T, Thompson M, Tran D. Metastatic-free survival and overall survival in prostate cancer [abstract]. Presented at: International Society for Pharmacoeconomics and Outcomes Research; 2015 May 16-20; Philadelphia, PA. Abstract PRM22.
   Google Scholar
• Xie W, Sweeney C, Regan M, et al. Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) [abstract]. Presented at: annual meeting of European Society of Medical Oncology; 2016 Oct 7-11; Copenhagen, Denmark. Abstract 707-O.
   Google Scholar
• van Soest RJ, de Wit R. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials. BMC Medicine. 2015;13:304.
   PubMed Web of Science ®Google Scholar